CJC-1295 (Without DAC)
CJC-1295 (without DAC) is a growth hormone–releasing hormone (GHRH) analog. It stimulates the pituitary gland to release endogenous growth hormone in a physiologic pulsatile pattern.
- IGF-1 signaling
- Recovery pathways
- Lean body mass maintenance
- Recovery support
- Age-related GH decline evaluation
Lab evaluation may be required.
Compounded peptide therapy is not FDA-approved for disease treatment. Prescribed only after physician review.
- Subcutaneous injection
- Typically administered daily
- Monitoring may include IGF-1 levels
Initial evaluation: $99
Medication prescribed only if clinically appropriate.
How It Works
You’ll begin with a brief virtual consultation with a licensed medical provider, who will review your medical history and determine whether this therapy may be appropriate for you.
If treatment is recommended, your prescription is sent to a licensed U.S. compounding pharmacy and shipped directly to your home, typically within 3–7 business days.
Consultation Cost
The total cost is $300, which includes:
If a peptide therapy is not clinically appropriate, there is no charge for the visit.
- All therapies are prescribed only when clinically appropriate and based on physician evaluation.
Frequently Asked Questions
CJC-1295 (without DAC) is not FDA-approved for disease treatment and is prescribed only after medical evaluation.
It may be legally prescribed as a compounded peptide under physician supervision when clinically appropriate.
It is typically given as a subcutaneous injection, often on a daily schedule as determined by a physician.
Individuals with hormone-sensitive conditions or underlying health concerns should undergo proper screening before use.
